原发性醛固酮增多症患者的髋部骨折——一项瑞典全国性研究
这项基于瑞典全国人群的匹配队列研究纳入2419例原发性醛固酮增多症患者与24187名年龄性别匹配对照,平均随访8±5年,发现患者髋部骨折风险增加55%(HR 1.55 [1.18-2.03]),女性、诊断时年龄>56岁及诊断时已有心血管病者风险更高,接受肾上腺切除术者风险未升高,而使用盐皮质激素受体拮抗剂者风险仍较高。
要点
- 原发性醛固酮增多症患者髋部骨折风险较对照增加55%(HR 1.55 [1.18-2.03])。
- 女性(HR 1.76)、诊断时>56岁(HR 1.62)及诊断时已有心血管病(HR 2.15)者风险更高。
- 接受肾上腺切除术者风险未高于对照(HR 0.84 [0.35-2.0]),使用盐皮质激素受体拮抗剂者风险仍较高(HR 1.84 [1.20-2.83])。
核心结论
- 原发性醛固酮增多症与髋部骨折风险增加相关,尤其在女性、诊断时年龄超过56岁及诊断时已有心血管病的患者中。
- 接受盐皮质激素受体拮抗剂治疗的患者似乎髋部骨折风险增加,而肾上腺切除术可能具有保护作用。
研究设计与样本
- 研究为基于瑞典全国人群的匹配队列研究,纳入1997年至2019年2419例原发性醛固酮增多症患者和24187名年龄与性别匹配的普通人群对照。
- 髋部骨折通过瑞典国家患者登记处的ICD编码识别,估计了新发髋部骨折的风险比(HR),并校正了既往骨折、社会经济因素、糖尿病、骨质疏松、甲状旁腺功能亢进和心血管病。
- 按年龄(18-56岁和>56岁)、性别、基线心血管病及原发性醛固酮增多症治疗方式进行了亚组配对比较。
主要发现
- 在平均8±5年随访期间,64例(2.6%)原发性醛固酮增多症患者在诊断后发生髋部骨折,对照组为401例(1.7%)。
- 校正后,原发性醛固酮增多症患者髋部骨折风险较对照增加55%(HR 1.55 [1.18-2.03])。
- 女性患者HR为1.76(95%CI 1.24-2.52),年龄>56岁患者HR为1.62(95%CI 1.21-2.17),诊断时已有心血管病患者HR为2.15(95%CI 1.37-3.37)。
- 接受肾上腺切除术的患者风险未高于对照(HR 0.84 [95%CI 0.35-2.0]),而接受盐皮质激素受体拮抗剂治疗的患者风险仍较高(HR 1.84 [95%CI 1.20-2.83])。
关键数值与推荐
- 原发性醛固酮增多症患者与对照相比髋部骨折风险HR 1.55(95%CI 1.18-2.03)。
- 女性患者HR 1.76(95%CI 1.24-2.52),年龄>56岁患者HR 1.62(95%CI 1.21-2.17),诊断时已有心血管病患者HR 2.15(95%CI 1.37-3.37)。
- 肾上腺切除术治疗者HR 0.84(95%CI 0.35-2.0),盐皮质激素受体拮抗剂治疗者HR 1.84(95%CI 1.20-2.83)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In this large population-based matched cohort study, patients with primary aldosteronism were at increased risk of hip fracture, particularly subgroups traditionally considered at higher risk of osteoporosis such as women, patients older than 56 years at diagnosis, patients with established cardiovascular disease at diagnosis, and patients treated with MRA. PURPOSE: Previous studies suggest that primary aldosteronism (PA) is associated with dysregulated bone homeostasis. The aim of this study was to evaluate the incidence of hip fractures in patients with PA. METHODS: We studied a nationwide cohort of 2419 patients with PA (1997-2019) and 24 187 age and sex matched controls from the general population. Hip fractures were identified by ICD codes in the Swedish National Patient Register. We estimated hazard ratios (HRs) for incident hip fractures, adjusted for prior fractures, socioeconomic factors, diabetes, osteoporosis, hyperparathyroidism, and cardiovascular disease (CVD). Pairwise subgroup comparisons were performed by age (18-56 and > 56 years), sex, CVD at baseline, and treatment for PA. RESULTS: During a mean follow up of 8 ± 5 years, 64 (2.6%) patients had a hip fracture after being diagnosed with PA, compared to 401 (1.7%) controls. After adjustments, PA was associated with a 55% increased risk of hip fracture compared to controls (HR 1.55 [1.18-2.03]). HRs were increased in women (HR 1.76 [95% CI 1.24-2.52]), patients aged > 56 years (HR 1.62 [95% CI 1.21-2.17]), and patients with CVD at diagnosis (HR 2.15 [95% CI 1.37-3.37]). PA patients treated with adrenalectomy did not have higher risk than controls (HR 0.84 [95% CI 0.35-2.0]), while patients treated with mineralocorticoid receptor antagonists (MRA) retained a greater risk (HR 1.84 [95% CI 1.20-2.83]). CONCLUSION: PA is associated with increased hip fracture risk, especially in women, patients diagnosed after the age of 56 years and patients with established CVD at diagnosis. Also, patients treated with MRA seem to have an increased risk of hip fractures, while adrenalectomy may be protective.
引用
- Gkaniatsa E, Sandström TZ, Rosengren A, et al. Hip fractures in patients with primary aldosteronism - a Swedish nationwide study. Osteoporos Int. 2024. PMID: 38839656. doi:10.1007/s00198-024-07132-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。